<DOC>
	<DOCNO>NCT00209274</DOCNO>
	<brief_summary>EVEREST II Randomized Controlled Trial ( RCT ) prospective , multi-center , randomize study MitraClip® System treatment mitral valve regurgitation , randomize patient MitraClip mitral valve surgery . The EVEREST II High Risk Registry ( HRR ) study prospective multi-center study MitraClip System treatment mitral valve regurgitation high surgical risk patient . Enrollment RCT HRR close . A continued access prospective , multi-center study ( REALISM ) MitraClip System surgical population ( non-high risk arm ) high surgical risk population ( high risk arm ) ongoing . Enrollment non-high risk arm REALISM close . Enrollment high risk arm REALISM ongoing . Patients enrol EVEREST II undergo 30-day , 6-month , 12-month , 18-month 24-month clinical echocardiographic follow-up , annually 5 year .</brief_summary>
	<brief_title>Pivotal Study Percutaneous Mitral Valve Repair System</brief_title>
	<detailed_description>Prospective , multi-center , randomize study safety effectiveness endovascular approach treatment mitral valve regurgitation use Evalve Cardiovascular Valve Repair System ( MitraClip® implant ) . A minimum 279 evaluable patient randomize 2:1 MitraClip mitral valve surgery , respectively , required test primary safety effectiveness endpoint RCT . Enrollment RCT complete . 60 roll-in patient enrol EVEREST II RCT . 38 clinical site throughout US Canada participate RCT HRR . 37 US site participate REALISM . The RCT power test hypothesis MitraClip superiority safety non-inferiority effectiveness compare mitral valve repair replacement surgery . The HRR power show low mortality 30 day MitraClip predict surgical mortality .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Key Inclusion/ Patients Grade 3 ( moderate severe ) Grade 4 ( severe ) mitral regurgitation ( MR ) base American Society Echocardiography guideline : Are 18 year old . Symptomatic If asymptomatic , must new onset atrial fibrillation , pulmonary hypertension , evidence leave ventricular dysfunction Are candidate mitral valve surgery Are candidate transseptal catheterization Primary regurgitant jet must originate malcoaptation A2 P2 scallop mitral valve Appropriate valve anatomy MitraClip Does need cardiac surgery emergency surgery Did experience myocardial infarction prior 12 week endovascular procedure prior 30 day Mitral valve orifice area ≥ 4 cm2 Do renal insufficiency Echocardiographic evidence intracardiac mass , thrombus vegetation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Mitral Valve Insufficiency</keyword>
	<keyword>Mitral Valve Regurgitation</keyword>
	<keyword>Mitral Valve Incompetence</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Insufficiency</keyword>
	<keyword>Mitral Valve</keyword>
	<keyword>MR</keyword>
	<keyword>Mitral Valve Prolapse</keyword>
	<keyword>Edge Edge ( E2E )</keyword>
	<keyword>Alfieri Technique</keyword>
	<keyword>MitraClip</keyword>
	<keyword>Functional MR</keyword>
	<keyword>Degenerative MR</keyword>
	<keyword>Echocardiogram</keyword>
	<keyword>CAD - Coronary Artery Disease</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>EVEREST</keyword>
	<keyword>EVEREST I</keyword>
	<keyword>EVEREST II</keyword>
	<keyword>REALISM</keyword>
</DOC>